BPC-157 and TB-500 are the most widely stacked peptides in the research community. The combination has a sensible mechanistic rationale — the two compounds address tissue repair through different and complementary pathways — but the human evidence base is more limited than the community discussion might suggest.
Understanding what's well-supported versus what's extrapolated from animal data matters for setting realistic expectations.
What each compound does independently
BPC-157 — the local repair signal
BPC-157 (Body Protection Compound-157) is a 15-amino acid synthetic peptide derived from a protein found in human gastric juice. It has an unusually broad preclinical research portfolio spanning tendon and ligament healing, gut mucosal repair, muscle tissue recovery, and anti-inflammatory activity.
Its primary mechanisms include upregulation of vascular endothelial growth factor (VEGF) — driving new blood vessel formation at injury sites — and modulation of nitric oxide signalling. The angiogenesis effect is particularly relevant to healing: damaged tissue often becomes ischaemic, and restoring blood supply is a critical bottleneck in the repair process.
180+ published studies, predominantly animal models. Human data consists of a small number of pilot studies, most without control groups. The FDA placed BPC-157 in Category 2 in 2023 (significant safety concerns, insufficient human data), though the February 2026 RFK Jr. policy reversal cleared 14 peptides including BPC-157 for legal compounding again. The preclinical data is extensive and mechanistically compelling. Human validation is limited.
TB-500 — the systemic repair signal
TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring peptide found in virtually every human cell. Where BPC-157 primarily drives localised tissue repair through angiogenesis, TB-500 works through a different mechanism: sequestering actin (a protein critical for cell structure and migration) and enabling cells to move into damaged areas more effectively.
TB-500's actin-regulatory mechanism drives cell migration and proliferation at injury sites. It also reduces inflammation and has documented effects on cardiac repair in animal models — one of the more interesting findings in its research portfolio.
Why the combination makes sense
The complementary mechanisms are the foundation of why this stack is so widely used. BPC-157 creates the vascular infrastructure at the injury site — new blood vessels that restore oxygen and nutrient supply. TB-500 enables cells to actually migrate into and populate the repaired tissue. They address sequential steps in the healing process rather than competing for the same pathway.
| Mechanism | BPC-157 | TB-500 |
|---|---|---|
| Primary action | Angiogenesis, VEGF upregulation | Actin sequestration, cell migration |
| Best for | Local repair, gut healing, tendon | Systemic repair, muscle, cardiac |
| Route preference | Local injection near injury | Subcutaneous — systemic distribution |
| Inflammation | Anti-inflammatory | Anti-inflammatory (different pathway) |
| Evidence quality | Extensive animal, limited human | Extensive animal, limited human |
Dosing protocols
The following protocols are drawn from published research and community experience. They are not FDA-approved dosing guidelines — no such guidelines exist for either compound.
| Protocol | BPC-157 dose | TB-500 dose | Duration |
|---|---|---|---|
| Acute injury | 250–500 mcg/day | 2–2.5 mg 2–3x/week | 4–8 weeks |
| Recovery maintenance | 250 mcg/day | 2 mg weekly | 8–12 weeks |
| Gut healing (BPC only) | 250 mcg oral/day | N/A | 4–8 weeks |
Administration note: BPC-157 for local musculoskeletal injuries is most effective injected subcutaneously near (not into) the injury site. TB-500 is typically injected subcutaneously in the abdomen for systemic distribution. They can be used on the same day but should not be combined into the same vial — they are reconstituted and administered separately.
What users realistically report
The community data for BPC-157/TB-500 is extensive and generally positive, particularly for tendon and ligament injuries where conventional recovery timelines are slow. The most consistently reported effects are accelerated return to training after soft tissue injuries and reduced localised pain and inflammation.
Gut healing is a strong secondary use case — BPC-157 specifically has well-documented gastroprotective effects, and oral administration (which achieves meaningful gut tissue concentrations via the arginate salt form) is widely used for IBD, leaky gut, and NSAID-related gut damage.
The important caveat: most positive community reports come from people who are also following other recovery best practices — appropriate load management, nutrition, sleep. Isolating the peptide contribution from these confounders in anecdotal reports is genuinely difficult.
TB-500 promotes angiogenesis — new blood vessel formation. This mechanism is beneficial for healing, but angiogenesis also supports tumour growth. There is no evidence that TB-500 causes cancer, but in individuals with undiagnosed malignancy, pro-angiogenic compounds are a theoretical concern. Anyone with a personal or strong family history of cancer should discuss this with a physician before using TB-500.
Sourcing quality matters more than most compounds
BPC-157 is one of the most counterfeited and adulterated compounds in the research market — high demand, simple labelling, and minimal enforcement create a supply chain quality problem. The arginate salt form (used for oral administration) and the standard injectable form must be distinguished — they are not interchangeable. COA verification from independent labs is non-negotiable.